Hemay 181
Alternative Names: Hemay-181Latest Information Update: 19 Jul 2024
At a glance
- Originator Ganzhou Hemay Pharmaceutical
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 Mar 2023 Ganzhou Hemay Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease) in China (IV) in March 2023 (NCT05749432)
- 01 Mar 2023 Preclinical trials in Solid tumours in China (IV) prior to March 2023